Resalis Therapeutics is a biopharma company focused on the development of antisense oligonucleotide (ASO) therapies to treat metabolic disorders, including MAFLD/NAFLD/NASH, obesity, and cancer. Resalis is applying LNA (locked nucleic acid) technology to inhibit miR-22 activity and restore a healthy homeostat in livers affected by metabolic disorders. miR-22 is a key player in the regulation […]

View post to subscribe to site newsletter.

Comanche Biopharma is developing novel siRNA (Small interfering RNA) compounds to treat preeclampsia via gene silencing. The protein sFLT-1 is believed to be the cause of preeclampsia. This protein, produced by the placenta and measurable in the plasma of pregnant women, is both diagnostic and prognostic for preeclampsia and is causally responsible for its disease […]

View post to subscribe to site newsletter.

NextRNA Therapeutics was founded in 2020 to pursue non-coding RNAs as a new class of therapeutic target for diseases including cancer, infectious diseases, and autoimmune disorders. There are many RNAs that do not make proteins, called non-coding RNAs (ncRNA). These ncRNAs are able to regulate essential processes and when altered cause disease. NextRNA has developed […]

View post to subscribe to site newsletter.